<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070265</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02722</org_study_id>
    <secondary_id>MDA-ID-02636</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000331853</secondary_id>
    <nct_id>NCT00070265</nct_id>
  </id_info>
  <brief_title>Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer</brief_title>
  <official_title>A Multi-Institutional Phase II Trial Of Neoadjuvant Capecitabine (XELODA) And Oxaliplatin (ELOXATIN) For Resectable Colorectal Metastases In The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as capecitabine and oxaliplatin, use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving capecitabine and oxaliplatin&#xD;
      before surgery may shrink the tumor so that it can be removed. Giving capecitabine and&#xD;
      oxaliplatin after surgery may kill any remaining tumor cells. This phase II trial is studying&#xD;
      how well capecitabine and oxaliplatin work when given before and after surgery in treating&#xD;
      patients with resectable liver metastases that is secondary to colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy and toxicity of neoadjuvant and adjuvant capecitabine and&#xD;
      oxaliplatin in patients with resectable liver metastases secondary to colorectal cancer who&#xD;
      are undergoing surgery.&#xD;
&#xD;
      II. Determine the rates of R0 resection in patients treated with this regimen before surgery.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate in patients treated with this regimen. II. Determine the&#xD;
      resectability in the subsets of patients defined as resectable preoperatively and treated&#xD;
      with this regimen.&#xD;
&#xD;
      III. Determine improvement in survival associated with downstaging based on metastatic&#xD;
      colorectal prognostic score in patients treated with this regimen.&#xD;
&#xD;
      IV. Determine the disease-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
      V. Correlate drug-specific biomarkers with clinical response in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral&#xD;
      capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical&#xD;
      resection of the tumor.&#xD;
&#xD;
      Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional&#xD;
      courses of oxaliplatin and capecitabine after surgery.&#xD;
&#xD;
      Patients are followed at 4-6 weeks after surgery, every 3 months for 2 years, every 4 months&#xD;
      for 1 year, every 6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 80 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete resection (R0 resection)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The design of Thall and Simon will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate assessed using RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resectability in the subsets defined as resectable preoperatively</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in survival associated with downstaging based on metastatic colorectal prognostic score</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positron emission tomography response rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (oxaliplatin, capecitabine, and surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.&#xD;
Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (oxaliplatin, capecitabine, and surgery)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (oxaliplatin, capecitabine, and surgery)</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Treatment (oxaliplatin, capecitabine, and surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (oxaliplatin, capecitabine, and surgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed hepatic colorectal metastasis by percutaneous hepatic biopsy&#xD;
&#xD;
               -  Imaging evidence of liver metastasis by CT helical scan&#xD;
&#xD;
          -  Resectable disease, as determined by a surgeon with hepatic surgery expertise (at&#xD;
             least 10 resections performed per year)&#xD;
&#xD;
               -  Resectable, defined as a sparing of 2 adjacent liver segments with adequate&#xD;
                  vascular inflow and outflow and hepatic remnant volume&#xD;
&#xD;
               -  Minor resections (less than a hemihepatectomy) or major resections&#xD;
                  (hemihepatectomy or extended hepatectomy) allowed&#xD;
&#xD;
               -  Bilobar resection allowed, including atypical resections&#xD;
&#xD;
          -  No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen,&#xD;
             and pelvis&#xD;
&#xD;
          -  Performance status - Zubrod 0-1&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 300 IU/L&#xD;
&#xD;
          -  No preexisting chronic hepatic disease (e.g., chronic active hepatitis or cirrhosis)&#xD;
             that would preclude surgical resection of metastases&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except completely resected nonmelanoma&#xD;
             skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No preexisting grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent sargramostim (GM-CSF)&#xD;
&#xD;
          -  More than 6 months since prior adjuvant fluorouracil-based chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for liver metastasis&#xD;
&#xD;
          -  No prior oxaliplatin for colorectal cancer&#xD;
&#xD;
          -  No prior or concurrent hepatic artery infusion chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior or concurrent radiotherapy for metastatic disease&#xD;
&#xD;
          -  No prior or concurrent radiofrequency ablation for metastatic disease&#xD;
&#xD;
          -  No prior or concurrent cryotherapy/other ablative techniques for metastatic disease&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent oral anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Nicolas Vauthey</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

